Isomorphic Labs, a company specialized in drug discovery and affiliated with Alphabet (the parent company of Google), revealed that clinical trials on humans for a drug designed entirely by the company with artificial intelligence will begin by the end of this year.
The company’s founder, Demis Hassabis, said in a statement in this regard that discovering a single drug usually takes 5 to 10 years, and his company may be able to speed up this process 10-fold, which will create a huge revolution in human health.
He explained that “Isomorphic Labs” focuses on “oncology, cardiovascular diseases, neurodegeneration, and all major diseases,” expressing his belief that “the company will begin trials of its first drug by the end of this year.”
Hassabis stated that within 3 years there will be “billions” of artificial intelligence agents who “negotiate with each other on behalf of the seller and the customer,” adding that this will require rethinking the Internet itself.
It is noteworthy that “Isomorphic Labs” was founded in 2021 as a spin-off from Google’s artificial intelligence research company, “DeepMind,” but it is still a wholly owned subsidiary of Alphabet.
The company’s huge potential has attracted major pharmaceutical companies, which are looking to reduce costs and increase the efficiency of the expensive drug development process.